Vertex Pharmaceuticals Incorporated company logo

# RNN 2nd Gen Model Vertex Pharmaceuticals Incorporated Pharmaceutical preparations

Prediction models:
Subscribe >> Deal exit on
Jan. 24, 2020
Deal entry on
Jan. 24, 2020
1.28%Expected margin
72.22% successful of 54 deals
$ 229.06 Last close price
at 24-jan-2020

VRTX

Model's trade recommendations 3.04% Return for period

-11.36% Annual return

$38.09B Market Cap

β 1.44  

VRTX

Model (following trade recommendations)

VRTX

Underlying stock

S&P 500

Index
Return for period 3.04%
4.00%
1.78%
52wk return -20.62%
20.88%
16.82%
52wk Range
164.61—235.83
2000.54—2399.63
Sortino ratio -0.39
Sharpe ratio -0.37
Norm. RMSE 1.36%
Downside risk 22.86%
Volatility 0.00%
  • STRONG BUY Analysts consensus recommendation

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Vertex Pharmaceuticals Incorporated (VRTX) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 30, 2015.

Market data for VRTX model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a regular basis.

Float 250M
P/E 124.56
Shares Outstanding 255M
% Held by Insiders 1.80%
% Held by Institutions 94.80%
EPS (last reported FY) $0.80
EPS (last reported Q) $0.54
EPS, estimated (last reported Q) $0.28
Total revenues $2 B
Net income $0 B